Frédérique Frouin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frédérique Frouin has a total of 579 co-authors. Here are the top co-authors by number of shared publications:
- Nadjia Kachenoura
Laboratoire d'Imagerie Biomédicale (LIB) Sorbonne Université, INSERM, CNRS Paris France
28 shared publications A. Herment
24 shared publications- Elie Mousseaux
Université Paris cité, PARCC, INSERM Paris France
24 shared publications - Edmond Kahn
Institut National de la Santé et de la Recherche Médicale U494, Centre Hospitalier Universitaire Pitié-Salpêtrière, 75634 Paris, France
16 shared publications Fanny Orlhac
13 shared publications- Olivier Lucidarme
Pitié-Salpêtrière Hospital (France)
13 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Elsevier in Journal of Voice
Scoping Review of Multiparametric Measures for Assessing Voice Quality in Voice Disorders: Focus on Continuous Speech
- 17 April 2026
- Published by Elsevier in Journal of Voice
Open AccessScoping Review of Multiparametric Measures for Assessing Voice Quality in Voice Disorders: Focus on Continuous Speech
- 15 June 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (11) , 8142-8154
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy
Objectives To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Materials and methods Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases. Results Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction. Conclusion Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC. Clinical relevance statement A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes. Key Points • Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. • Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. • Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.
- 15 June 2023
- Published by Springer Nature in European Radiology
- Vol. 33 (11) , 8142-8154
Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy
Objectives To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Materials and methods Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases. Results Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction. Conclusion Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC. Clinical relevance statement A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes. Key Points • Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. • Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. • Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Textural and shape analysis is gaining considerable interest in medical imaging, particularly to identify parameters characterizing tumor heterogeneity and to feed radiomic models. Here, we present a free, multiplatform, and easy-to-use freeware called LIFEx, which enables the calculation of conventional, histogram-based, textural, and shape features from PET, SPECT, MR, CT, and US images, or from any combination of imaging modalities. The application does not require any programming skills and was developed for medical imaging professionals. The goal is that independent and multicenter evidence of the usefulness and limitations of radiomic features for characterization of tumor heterogeneity and subsequent patient management can be gathered. Many options are offered for interactive textural index calculation and for increasing the reproducibility among centers. The software already benefits from a large user community (more than 800 registered users), and interactions within that community are part of the development strategy.Significance: This study presents a user-friendly, multi-platform freeware to extract radiomic features from PET, SPECT, MR, CT, and US images, or any combination of imaging modalities. Cancer Res; 78(16); 4786–9. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Textural and shape analysis is gaining considerable interest in medical imaging, particularly to identify parameters characterizing tumor heterogeneity and to feed radiomic models. Here, we present a free, multiplatform, and easy-to-use freeware called LIFEx, which enables the calculation of conventional, histogram-based, textural, and shape features from PET, SPECT, MR, CT, and US images, or from any combination of imaging modalities. The application does not require any programming skills and was developed for medical imaging professionals. The goal is that independent and multicenter evidence of the usefulness and limitations of radiomic features for characterization of tumor heterogeneity and subsequent patient management can be gathered. Many options are offered for interactive textural index calculation and for increasing the reproducibility among centers. The software already benefits from a large user community (more than 800 registered users), and interactions within that community are part of the development strategy.Significance: This study presents a user-friendly, multi-platform freeware to extract radiomic features from PET, SPECT, MR, CT, and US images, or any combination of imaging modalities. Cancer Res; 78(16); 4786–9. ©2018 AACR.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Well-known software programs that enable the calculation of radiomic features and associated characteristics.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Well-known software programs that enable the calculation of radiomic features and associated characteristics.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Examples of published articles that used LIFEx to produce results with biological or clinical impact.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Examples of published articles that used LIFEx to produce results with biological or clinical impact.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Distribution of SUVpeak, Entropy, HGZE, and SRE in healthy tissues and in tumors as a function of the voxel size: in blue for 4x4x4 mm3, in green for 2x2x2 mm3 and in pink for 1x1x1 mm3.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Distribution of SUVpeak, Entropy, HGZE, and SRE in healthy tissues and in tumors as a function of the voxel size: in blue for 4x4x4 mm3, in green for 2x2x2 mm3 and in pink for 1x1x1 mm3.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Demonstration of the use of LIFEx for radiomic feature extraction from a PET/MR scan from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
A real-time complete example of radiomic feature calculation from a PET/MR scan, where the same volumes of interest are used to extract PET and MR radiomic features.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDemonstration of the use of LIFEx for radiomic feature extraction from a PET/MR scan from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
A real-time complete example of radiomic feature calculation from a PET/MR scan, where the same volumes of interest are used to extract PET and MR radiomic features.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Distribution of SUVpeak, Entropy, HGZE, and SRE in healthy tissues and in tumors as a function of the voxel size: in blue for 4x4x4 mm3, in green for 2x2x2 mm3 and in pink for 1x1x1 mm3.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Distribution of SUVpeak, Entropy, HGZE, and SRE in healthy tissues and in tumors as a function of the voxel size: in blue for 4x4x4 mm3, in green for 2x2x2 mm3 and in pink for 1x1x1 mm3.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Examples of published articles that used LIFEx to produce results with biological or clinical impact.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
Examples of published articles that used LIFEx to produce results with biological or clinical impact.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Demonstration of the use of LIFEx for radiomic feature extraction from a PET/MR scan from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
A real-time complete example of radiomic feature calculation from a PET/MR scan, where the same volumes of interest are used to extract PET and MR radiomic features.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessDemonstration of the use of LIFEx for radiomic feature extraction from a PET/MR scan from LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity
A real-time complete example of radiomic feature calculation from a PET/MR scan, where the same volumes of interest are used to extract PET and MR radiomic features.